Ontology highlight
ABSTRACT:
SUBMITTER: Galban S
PROVIDER: S-EPMC5669819 | biostudies-literature | 2017 Nov
REPOSITORIES: biostudies-literature
Galbán Stefanie S Apfelbaum April A AA Espinoza Carlos C Heist Kevin K Haley Henry H Bedi Karan K Ljungman Mats M Galbán Craig J CJ Luker Gary D GD Dort Marcian Van MV Ross Brian D BD
Molecular cancer therapeutics 20170803 11
Responses to targeted therapies frequently are brief, with patients relapsing with drug-resistant tumors. For oncogenic MEK and BRAF inhibition, drug resistance commonly occurs through activation of PI3K/AKT/mTOR signaling and immune checkpoint modulation, providing a robust molecular target for concomitant therapy. Here, we evaluated the efficacy of a bifunctional kinase inhibitor (ST-162) that concurrently targets MAPK and PI3K signaling pathways. Treatment with ST-162 produced regression of m ...[more]